Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer
British journal of surgery2018Vol. 105(3), pp. 192–202
Citations Over TimeTop 1% of 2018 papers
Tomoki Ebata, Satoshi Hirano, Masaru Konishi, Katsuhiko Uesaka, Y. Tsuchiya, Masayuki Ohtsuka, Yuji Kaneoka, Masakazu Yamamoto, Yoshiyasu Ambo, Yasuhiro Shimizu, Fumiaki Ozawa, Akira Fukutomi, Masahiko Ando, Y Nimura, Masato Nagino, Shoji Nakamori, Tetsuo Ajiki, Hideo Baba, R Yamaguchi, Manabu Kawai, Hiroaki Nagano, Fumihiko Miura, Takaaki Arai, Yoshiro Nishiwaki, S. Kawasaki, Hiroyuki Shinchi, Mitsugi Shimoda, Yusuke Yamamoto, Itaru Endo, Shuji Isaji, Takehito Otsubo, Shin Ishihara, Takeshi Takahara, Mitsuo Shimada, Michiaki Unno, M Imamura, Nobuhiro Ohkochi, Yoshiaki Murakami, Jiro Fujimoto, Shinichi Ikuta, Y Fujino, Minoru Uebayashi, Shuichi Ishiyama, Norihisa Takakura, Yusuke Kumamoto, Takehito Kato, Isaku Yoshioka, Shinji Üemoto, Katsuhiko Yanaga
Abstract
The survival probability in patients with resected bile duct cancer was not significantly different between the gemcitabine adjuvant chemotherapy group and the observation group. Registration number: UMIN 000000820 (http://www.umin.ac.jp/).
Related Papers
- The Survival Outcome and Prognostic Factors for Extrahepatic Bile Duct Cancer Focused on Worse Behavior of Middle Bile Duct Cancer(2012)
- The application of PTC-CT in SRT treatment of bile duct cancer(2001)
- [Surgical treatment for the upper and middle bile duct cancer].(1997)
- → Prognostic Comparison of the Longitudinal Margin Status in Distal Bile Duct Cancer: R0 on First Bile Duct Resection vs. R0 After Additional Resection(2018)
- → Bile salt export pump expression in bile duct tissues of rats with bile duct cancer(2015)